HYLOMORPH AG Revenue and Competitors
Estimated Revenue & Valuation
- HYLOMORPH AG's estimated annual revenue is currently $4M per year.
- HYLOMORPH AG's estimated revenue per employee is $251,000
Employee Data
- HYLOMORPH AG has 16 Employees.
- HYLOMORPH AG grew their employee count by 7% last year.
HYLOMORPH AG's People
Name | Title | Email/Phone |
---|
HYLOMORPH AG Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is HYLOMORPH AG?
Hylomorph is an innovative Medtech company engineering biomaterials to optimize the interface between implantable medical devices and tissues. Our goal is to transform the biocompatibility of implantable medical devices to improve the quality of life of patients and the quality of care by healthcare professionals, while reducing overall healthcare costs. The proprietary CellSense technology was developed in the cutting-edge laboratories of the Swiss Federal Institute of Technology (ETH Zurich). Hylomorph's first product, Hylomate, has demonstrated outstanding performance in reducing foreign body reaction and fibrotic buildup in pre-clinical settings and preparations are currently being made for first-in-man clinical trials in Germany.
keywords:N/AN/A
Total Funding
16
Number of Employees
$4M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.4M | 16 | -11% | N/A |
#2 | $1.4M | 16 | N/A | N/A |
#3 | $1.4M | 16 | -11% | N/A |
#4 | $1.5M | 16 | 7% | N/A |
#5 | $1.4M | 17 | 6% | N/A |